ProCE Banner Activity

ECHELON-1: OS Analysis of First-line Brentuximab Vedotin + AVD vs ABVD in Advanced Classical Hodgkin Lymphoma

Slideset Download
Conference Coverage
With approximately 6 years of follow-up of ECHELON-1, addition of brentuximab vedotin to AVD significantly improved overall survival vs ABVD in patients with previously untreated advanced cHL.

Released: June 07, 2022

Expiration: June 06, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen

Seagen and Genmab